General MedicationsSUBCUTANEOUSStandard
OMVOH
MIRIKIZUMAB-MRKZ
Standard Dose
100MG/ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview OMVOH is listed in Drugs@FDA under application 761279 (BLA).
Review priority: STANDARD Marketing status: Prescription Active ingredient MIRIKIZUMAB-MRKZ Form and strength INJECTABLE;SUBCUTANEOUS - 100MG/ML Sponsor ELI LILLY AND CO Submission history Latest submission status date: 2025-10-23 00:00:00.
Structured Monograph
Clinical summary
Approval overview OMVOH is listed in Drugs@FDA under application 761279 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient MIRIKIZUMAB-MRKZ Form and strength INJECTABLE;SUBCUTANEOUS - 100MG/ML Sponsor ELI LILLY AND CO Submission history Latest submission status date: 2025-10-23 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.